Edition:
United States

CASI Pharmaceuticals Inc (CASI.OQ)

CASI.OQ on NASDAQ Stock Exchange Capital Market

1.37USD
4:00pm EDT
Change (% chg)

$-0.06 (-4.20%)
Prev Close
$1.43
Open
$1.41
Day's High
$1.42
Day's Low
$1.37
Volume
798
Avg. Vol
9,004
52-wk High
$1.73
52-wk Low
$0.84

Latest Key Developments (Source: Significant Developments)

Casi Pharmaceuticals says up to 28.9 mln shares of co's common stock may be offered for sale by selling stockholders
Friday, 2 Dec 2016 04:48pm EST 

Casi Pharmaceuticals Inc :Says up to 28.9 million shares of co's common stock may be offered for sale by selling stockholders - SEC filing.  Full Article

Casi Pharmaceuticals reports third quarter 2016 results
Monday, 14 Nov 2016 07:00am EST 

Casi Pharmaceuticals Inc : Casi Pharmaceuticals reports third quarter 2016 financial results .Q3 loss per share $0.03.  Full Article

Casi Pharmaceuticals Q2 loss per share $0.08
Monday, 15 Aug 2016 07:00am EDT 

Casi Pharmaceuticals Inc : Casi Pharmaceuticals reports second quarter 2016 financial results .Q2 loss per share $0.08.  Full Article

Casi Pharmaceuticals reports Q1 loss per share $0.04
Friday, 13 May 2016 07:16am EDT 

Casi Pharmaceuticals Inc : Casi Pharmaceuticals reports first quarter 2016 financial results .Q1 loss per share $0.04.  Full Article

CASI Pharmaceuticals Inc receives EU orphan drug designation for the use Of ENMD-2076
Wednesday, 14 Oct 2015 07:00am EDT 

CASI Pharmaceuticals Inc:Says Oncology drug candidate, ENMD-2076, has received Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of hepatocellular carcinoma.Designation provides CASI with 10 years of market exclusivity in EU after ENMD-2076 receives marketing authorization there.  Full Article

CASI Pharmaceuticals Inc to Raise $25.1 Million in Private Placement of Common Stock and Warrants
Monday, 21 Sep 2015 07:00am EDT 

CASI Pharmaceuticals Inc:Announced that it has entered into definitive agreements for a $25.1 million financing led by a China investment fund manager affiliated largest shareholder, IDG-Accel China Growth Fund III, L.P.The Company agreed to sell a total of 20,658,434 shares of common stock, at $1.190 per share and a total of 4,131,686 warrants, representing a 20% warrant coverage, with a purchase price of $0.125 per whole warrant share.The warrants will become exercisable three months after issuance at $1.69 per share exercise price, and will expire three years from the date the warrants become exercisable.  Full Article

CASI Pharmaceuticals files new drug clinical trial application with China FDA
Thursday, 4 Jun 2015 07:00am EDT 

CASI Pharmaceuticals:Files new drug clinical trial application with China FDA to expand U.S. development of enmd-2076 in fibrolamellar carcinoma.Says CASI on track to initiate U.S. phase 2 trial with enmd-2076 in flc by 3q2015.Says CASI expands patent estate for enmd-2076.  Full Article

More From Around the Web